Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Recent & Breaking News (NDAQ:VIRX)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sunesis Pharmaceuticals, Inc. (SNSS)

PR Newswire May 2, 2017

18 Biggest Mid-Day Losers For Tuesday

Benzinga.com  May 2, 2017

Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML

GlobeNewswire May 1, 2017

Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting

GlobeNewswire April 3, 2017

Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference

GlobeNewswire March 28, 2017

Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin

GlobeNewswire March 22, 2017

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights

GlobeNewswire March 9, 2017

Sunesis to Host Conference Call on March 9th to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights

GlobeNewswire March 2, 2017

Sunesis Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference

GlobeNewswire March 1, 2017

Sunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference

GlobeNewswire February 6, 2017

Sunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS-062 and Vosaroxin Programs

GlobeNewswire January 23, 2017

Sunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall Survival in Patients Age 60 Years and Older with Relapsed/Refractory AML at the ASH Annual Meeting

GlobeNewswire December 5, 2016

Sunesis Pharmaceuticals Announces Presentation of Results from Completed Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 at ASH Annual Meeting

GlobeNewswire December 5, 2016

Sunesis Pharmaceuticals Announces Presentations at ASH Annual Meeting

GlobeNewswire November 3, 2016

Sunesis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Highlights

GlobeNewswire November 3, 2016

Sunesis to Host Conference Call on November 3rd to Discuss Third Quarter 2016 Financial Results and Recent Highlights

GlobeNewswire October 27, 2016

Sunesis Announces Closing of Public Offerings and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire October 24, 2016

Sunesis Announces Pricing of $25 Million Offering of Securities

GlobeNewswire October 19, 2016

Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock

GlobeNewswire October 18, 2016

Sunesis Pharmaceuticals to Present at the Dawson James Securities 2nd Annual Small Cap Growth Stock Conference

GlobeNewswire October 18, 2016